Accentia Biopharmaceuticals Inc is a bio pharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. The Company has two product candidates entering or in Phase III clinical trials. Their first product candidate, SinuNase, has been developed as a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis which is a long-term inflammatory condition of the paranasal sinuses for which there is currently no FDA-approved therapy. They submitted an Investigational New Drug Application with the FDA for SinuNase in April 2005, and the Investigational New Drug Application was accepted by the FDA in May 2005. They expect to initiate Phase III trials for SinuNase later in calendar year 2005. Their second product candidate, Biovaxid, is a patient-specific cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. Biovaxid is currently in a pivotal Phase III clinical trial under an Investigational New Drug Application that they acquired from the National Cancer Institute in 2004. In addition to these product candidates, the company is also involved in pharmaceutical business with a portfolio of ten currently marketed products and a pipeline of products under development by third parties. Their goal is to utilize their vertically integrated business structure to cost-effectively and efficiently develop and commercialize innovative therapeutics that addresses unmet medical needs.
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.
Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.